BIOHAVEN LTD (BHVN) Stock News

Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force

The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory framework for crypto assets.

What's Going On With Merus Stock Monday?

Merus announced a research collaboration and license agreement with Biohaven.

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation

Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas. Announces multiple advancements across the...

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 43rd Annual J.P....

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates

BHV-1300 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD. Subcutaneous BHV-1300 achieved rapid...

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting

Reported expanded safety results from BHV-7000 Phase 1 multiple ascending dose studies, including the once-daily extended-release formulation being evaluated...

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

In the RESILIENT SMA study, taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function...

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial...

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy

The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease.

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN),a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

Biohaven Announces Proposed Public Offering of Common Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally...

Biohaven Stock Soars on Drug Trial Results: Time to Jump In?

Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug.